Dr. Sharifi on the Rationale to Evaluate the Correlation Between the Gut Microbiome and Aggressive Prostate Cancer

Video

In Partnership With:

Nima Sharifi, MD, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

Currently, the cause of aggressive prostate cancer remains unknown but is thought to be attributed to a mixture of genetic and environmental factors, Sharifi says. Moreover, prostate cancer is a common disease but only a fraction become lethal, Sharifi says. As such, a fraction of patients have indolent disease that does not require therapy, Sharifi explains.

Overall, the rationale for examining the gut microbiome in relation to aggressiveness of prostate cancer is based on trying to distinguish contributing factors for indolent and lethal prostate cancer and how to differentiate between the etiologies, Sharifi concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,